CooperCompanies (COO): Shares Drop 14 Percent on Guidance Cut

CooperCompanies closed at $55.01 on 10 September 2026, down roughly 14% in a single session, after a fiscal third-quarter report that beat on adjusted earnings. The beat was not the point. Two things landed alongside it: full-year adjusted earnings guidance was cut to $4.51-$4.55 against a consensus nearer $4.63, and the board ended its strategic review of CooperSurgical and decided to keep the business. The first is a 2% trim. The second removes the entire reason a meaningful slice of the shareholder register was there.

Put plainly: a company that grew revenue 1% and beat on earnings lost about a seventh of its market value, because the market was not valuing the quarter. It was valuing the possibility of two companies. CooperCompanies is now to be valued as one.

What actually happened

Consolidated revenue for the quarter ended 31 July 2026 was $1.066bn, up approximately 1% on both a reported and an organic basis. Within that, CooperVision — the contact lens business and the larger half — delivered $717.0m, flat year on year. CooperSurgical grew 2% to $349.2m, with 3% organic growth led by a 5% increase in fertility revenue. Adjusted diluted earnings per share came in at $1.15, up 4% and modestly ahead of the Street.

The headline GAAP number needs handling with care, because it is the sort of figure that produces a wrong thesis if taken at face value. GAAP diluted earnings per share of $2.24, against $0.49 in the comparable quarter, looks like a transformation. It is not one. The gap is overwhelmingly a $307.2m discrete tax benefit arising from a favourable UK tax examination — a one-off, non-operating item. The operating business earned $1.15 on an adjusted basis and grew 4%. Anyone comparing this quarter's GAAP figure with a prior-period adjusted figure, or building a margin argument on the difference, is comparing two different things.

Cash generation was genuinely strong. Free cash flow of $273.0m was a quarterly record, up 66% year on year, taking the year-to-date figure to roughly $528m. The company repurchased $339.1m of stock during the quarter — more than the free cash flow it generated — and the board raised the repurchase authorisation from $2bn to $3bn.

The guidance cut

Full-year fiscal 2026 adjusted earnings per share is now guided to $4.51-$4.55. The midpoint of $4.53 sits below the roughly $4.63 the market carried. Revenue guidance of $4.229bn-$4.252bn, midpoint $4.241bn, is well under a $4.31bn estimate.

The fourth quarter carries the damage. Management guided to consolidated revenue of $1.057bn-$1.08bn, representing 0% to 2% organic growth, and adjusted earnings per share of $1.05-$1.09. That midpoint of $1.07 compares with a consensus of about $1.19 — a gap of roughly 10%, which is a far heavier miss than the full-year trim implies, because three quarters are already in the bag.

The stated cause is a deliberate reduction of US channel inventory at CooperVision, which chief executive Al White framed as establishing a healthier foundation for fiscal 2027 — pulling sell-in below sell-through now so the channel is clean going into the new year. Layered on top are higher commercial investment, currency pressure and lower tariff refunds.

The review that ended without a deal

The board concluded unanimously that continued ownership of CooperSurgical serves shareholders better than the transaction proposals it received. The company was explicit about why the bids came in where they did: the sale process attracted significant interest, but valuations were affected by the arrival of a new competitor in the non-hormonal IUD market and by a recent fertility litigation settlement.

That is a more useful disclosure than it first appears. The assets were marketable, a price was discovered, and the price was judged inadequate against two identifiable and recent events. It does not say the business is unsaleable. It says the clearing price moved.

Why the market reacted the way it did

A 2% cut to full-year guidance does not produce a 14% share price move on its own. Three things compounded.

First, the quality of the cut. A trim driven by channel destocking is, in management's telling, a timing effect — inventory pulled out of the channel this year rather than demand lost. But channel corrections are notoriously hard to size from outside, and the market has seen enough of them to discount the claim that this one is a single quarter's worth. The Q4 earnings midpoint being 10% light rather than 2% light is the number that did the work.

Second, the destocking sits on top of a business already growing at 1%. Destocking is a recoverable problem when the underlying line is compounding at high single digits; it is a much less comfortable one when CooperVision is flat and the group's organic growth rounds to a rounding error. There is no growth cushion absorbing the hit.

Third, and largest: the sum-of-the-parts case is gone. A meaningful part of the register was underwriting a separation — vision care and surgical valued apart, each on the multiple its own peer set commands, with the conglomerate discount released. The board has now formally declined to do that. It converts a holding with an identified catalyst into a holding without one, and holders who owned the catalyst rather than the business have no reason to stay. That is the mechanism behind a move of this size on a modest guidance change.

The Openbook read

Running this through the five factors, the interesting result is that only two of them actually moved, and the ones that moved are not the ones the headline suggests.

Momentum takes the clearest hit. A gap-down of roughly 14% on event-driven volume resets trend and relative-strength measures at a stroke, and it does so on a name that was already not being rewarded for its cash generation. Momentum scores built on price and relative performance will read materially weaker after this print, and a gap of this size takes evidence to repair. The next evidence arrives in December.

Growth was weak before the print and remains weak. Revenue up 1% reported and organic, CooperVision flat, and Q4 guided to 0-2% organic. The read here barely changes, which is itself the problem: there was no growth score to lose, and nothing in this quarter argues for a better one. Fertility at 5% is the only line moving at a respectable rate, and it sits inside the segment the board has just confirmed it is keeping.

Profitability is the factor most likely to be misread, and it holds up better than the share price implies. Strip out the tax benefit and the operating picture is a business growing adjusted earnings 4% on 1% revenue growth — modest operating leverage, intact. Record quarterly free cash flow of $273m, up 66%, is a real improvement in cash conversion rather than an accounting artefact. Q4 margin guidance carries identified headwinds from commercial investment, currency and tariff refunds, which will compress the near-term reading. But the profitability score is not what broke here.

Solvency is where the review's conclusion has a second-order effect that is easy to miss. A sale of CooperSurgical would have delivered a large, discrete cash inflow — the fastest available route to deleveraging. Declining the bids means the balance sheet now improves only at the pace the operating business generates cash. That pace is respectable, at $528m year to date, but the company also spent $339.1m of it on buybacks in a single quarter and has just authorised another $1bn of capacity. Cash returned is cash not applied to debt. The solvency read is therefore not weaker on any reported metric, but its trajectory now depends entirely on organic cash generation and on how aggressively management uses the enlarged authorisation.

Reward/risk is the factor that has genuinely repriced, and the direction is not one-way. The downside case is straightforward: a low-growth medical device group, correcting channel inventory into a soft quarter, with the break-up optionality withdrawn and momentum broken. Against that, the price paid for the asset has fallen by a seventh while the cash generation improved, and the board has told the market it believes the shares are worth more than the bids it received — the extra $1bn of authorisation being the mechanism by which it intends to prove that. The skew has moved; whether it has improved depends almost entirely on whether the destocking really is confined to fiscal 2026.

Readers comparing this against other low-growth, high-cash-conversion medical names can set the factor profile side by side on the Openbook screener.

The read-across

The contact lens market is a tight oligopoly — CooperVision, Alcon, Bausch + Lomb and Johnson and Johnson's vision business between them account for the overwhelming majority of global supply. Channel inventory is not a company-specific phenomenon in a structure like that: distributors and optical retailers stock all four, and when one supplier decides its channel is too full, the question is whether its competitors have reached the same conclusion or are about to. A deliberate destock at the largest or second-largest player is a data point about the channel, not just about Cooper. Peers reporting into the autumn will be asked directly.

The second read-across is corporate rather than commercial, and it travels further. CooperCompanies ran a full strategic review, attracted real interest, discovered a price and walked away. Every medtech and diversified healthcare board currently under pressure to separate now has a live comparable showing that the bid environment for surgical and fertility assets is softer than sellers hoped — and two specific reasons why, in new IUD competition and fertility litigation. Boards that were planning to test the market may reconsider the timing. Shareholders agitating for break-ups have just been handed evidence that the separation trade can be declined.

Third, the litigation settlement cited as a valuation headwind is a sector-level fact, not a Cooper one, and tells holders of assisted-reproduction exposure elsewhere how acquirers are currently pricing legal tail risk in that category.

What to watch next

The near-term calendar is well defined. CooperCompanies' fiscal year ends on 31 October 2026, and the fourth-quarter and full-year report typically lands in early December. Three specific things matter in it.

• Whether the channel correction is finished. Management has framed the destock as clearing the way for fiscal 2027. The Q4 print, and more importantly the initial fiscal 2027 guidance issued alongside it, will show whether that was accurate or whether the reduction extends. Initial FY27 revenue and adjusted earnings guidance is the single most load-bearing disclosure of the next six months.
• CooperVision returning to growth. Flat is the number to beat. The segment needs to demonstrate that the underlying demand line was never the issue and that sell-through held while sell-in was cut. Watch the organic figure, not the reported one, given the currency movement management has already flagged.
• The pace of the buyback. With authorisation raised from $2bn to $3bn, the rate at which the company actually repurchases stock is management's most direct statement about its own view of value. Quarterly repurchase figures run at $339.1m in Q3; whether that accelerates, holds or slows tells you how seriously to take the board's implicit valuation argument.

Beyond that, watch the non-hormonal IUD competitive dynamic that the board explicitly named. If the new entrant's share gains prove limited, the valuation headwind cited for the failed sale process weakens — and the strategic question the board has just closed does not stay closed for ever.